126 related articles for article (PubMed ID: 19795215)
1. The impact of changes in hormone therapy on breast cancer incidence in the US population.
Coombs NJ; Cronin KA; Taylor RJ; Freedman AN; Boyages J
Cancer Causes Control; 2010 Jan; 21(1):83-90. PubMed ID: 19795215
[TBL] [Abstract][Full Text] [Related]
2. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
3. Declines in breast cancer after the WHI: apparent impact of hormone therapy.
Clarke CA; Glaser SL
Cancer Causes Control; 2007 Oct; 18(8):847-52. PubMed ID: 17619153
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and breast cancer risk in California.
Coombs NJ; Taylor R; Wilcken N; Fiorica J; Boyages J
Breast J; 2005; 11(6):410-5. PubMed ID: 16297085
[TBL] [Abstract][Full Text] [Related]
5. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
Simon JA; Nahum GG; Stanislaw H; Gaines T
Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
[TBL] [Abstract][Full Text] [Related]
6. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence.
Verkooijen HM; Bouchardy C; Vinh-Hung V; Rapiti E; Hartman M
Maturitas; 2009 Oct; 64(2):80-5. PubMed ID: 19709827
[TBL] [Abstract][Full Text] [Related]
7. Stopping menopausal hormone therapy: if breast cancer really decreased, why did colorectal cancer not increase?
Nahum GG; Stanislaw H; Simon JA
Maturitas; 2012 Apr; 71(4):354-9. PubMed ID: 22300685
[TBL] [Abstract][Full Text] [Related]
8. Risks of hormone therapy in the 50-59 year age group.
van de Weijer PH
Maturitas; 2008 May; 60(1):59-64. PubMed ID: 18556157
[TBL] [Abstract][Full Text] [Related]
9. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections.
Krieger N
Int J Epidemiol; 2008 Jun; 37(3):627-37. PubMed ID: 18375445
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
La Vecchia C
Breast; 2004 Dec; 13(6):515-8. PubMed ID: 15563861
[TBL] [Abstract][Full Text] [Related]
11. Women's awareness and knowledge of hormone therapy post-Women's Health Initiative.
Rigby AJ; Ma J; Stafford RS
Menopause; 2007; 14(5):853-8. PubMed ID: 17429334
[TBL] [Abstract][Full Text] [Related]
12. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
Li CI; Malone KE; Daling JR
Cancer Causes Control; 2006 Jun; 17(5):695-703. PubMed ID: 16633917
[TBL] [Abstract][Full Text] [Related]
13. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
14. Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up.
Barbaglia G; Macià F; Comas M; Sala M; del Mar Vernet M; Casamitjana M; Castells X
Menopause; 2009; 16(5):1061-4. PubMed ID: 19369903
[TBL] [Abstract][Full Text] [Related]
15. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication.
Guay MP; Dragomir A; Pilon D; Moride Y; Perreault S
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):17-27. PubMed ID: 16794994
[TBL] [Abstract][Full Text] [Related]
16. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002).
Barber CA; Margolis K; Luepker RV; Arnett DK
J Womens Health (Larchmt); 2004 Nov; 13(9):975-85. PubMed ID: 15665654
[TBL] [Abstract][Full Text] [Related]
17. HRT and breast cancer: impact on population risk and incidence.
Coombs NJ; Taylor R; Wilcken N; Boyages J
Eur J Cancer; 2005 Aug; 41(12):1775-81. PubMed ID: 16087330
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
19. Women's use of hormone therapy before and after the Women's Health Initiative: a psychosocial model of stability and change.
Gerend MA; Aiken LS; Erchull MJ; Lapin A
Prev Med; 2006 Sep; 43(3):158-64. PubMed ID: 16750263
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
